Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Novo Nordisk narrows 2026 outlook as Wegovy pill uptake cushions blow ...

Business restructuring Drug pricing Guidance lowered AI-generated analysis

πŸ“‰ Novo Nordisk expects full-year sales and operating profit to decline in 2026 at constant exchange rates.

πŸ’Š Strong uptake of the new oral Wegovy pill has partially offset lower US prices and generic competition abroad.

πŸ“‰ Sales of injectable Wegovy and Ozempic in the US fell as average prices dropped following the pricing agreement.

πŸ‘· CEO Maziar Mike Doustdar cut around 9,000 jobs as part of a restructuring aimed at saving billions of kroner.

βš”οΈ The company faces intensifying competition from Eli Lilly's orforglipron pill in the obesity market.

πŸ‡ΊπŸ‡Έ US demand for the oral drug became a rare bright spot with prescriptions rising through Q3 via cash-pay partners.

πŸ“‰ Novo Nordisk shares lost about 19% of their value over the past year as Eli Lilly overtook it in the obesity market.

Bullish Signals
  • Strong demand for the new oral Wegovy pill has partly offset lower US prices and generic competition, serving as a rare bright spot for the company.
  • Prescriptions for the oral Wegovy continued to rise through the third quarter, helped by cash-pay sales through NovoCare pharmacy and telehealth partners.
Risk Factors
  • The company expects full-year sales and operating profit to decline in 2026 at constant exchange rates.
  • Lower US prices following the pricing agreement with the Trump administration are driving revenue pressure for injectable products.
  • Expiry of semaglutide patents in markets including China, Canada, and Brazil exposes the company to generic competition.
  • Sales of injectable Wegovy and Ozempic in the US fell as average prices dropped significantly.
Full Analysis
Novo Nordisk has narrowed its full-year 2026 outlook, maintaining expectations for a decline in sales and operating profit at constant exchange rates. The company attributes this forecast to lower US prices resulting from a pricing agreement with the Trump administration and the expiry of semaglutide patents in key overseas markets including China, Canada, and Brazil. Despite the overall sales contraction, strong demand for its oral obesity drug, Wegovy, has served as a partial offset. The pill launched in the United States in January and saw rising prescriptions through the third quarter, driven by cash-pay sales channels via NovoCare pharmacy and telehealth partners. This growth contrasts with falling sales of injectable Wegovy and Ozempic in the US due to average price drops. CEO Maziar Mike Doustdar, who assumed leadership in 2025, has executed a restructuring plan that includes cutting approximately 9,000 jobs to save billions of kroner annually. The company is pivoting its strategy toward volume growth as prices decline across the obesity market, even as it faces intensifying competition from Eli Lilly's orforglipron pill and generic semaglutide abroad.